REQUEST FOR TECHNICAL CHANGE

AGENCY: Board of Pharmacy

RULE CITATION: 21 NCAC 46 .1819

DEADLINE FOR RECEIPT: January 13, 2021

<u>PLEASE NOTE:</u> This request may extend to several pages. Please be sure you have reached the end of the document.

The Rules Review Commission staff has completed its review of this Rule prior to the Commission's next meeting. The Commission has not yet reviewed this Rule and therefore there has not been a determination as to whether the Rule will be approved. You may call our office to inquire concerning the staff recommendation.

In reviewing this Rule, the staff recommends the following technical changes be made:

At line 8, please add an "and" after "Ribavirin."

Please retype the rule accordingly and resubmit it to our office at 1711 New Hope Church Road, Raleigh, North Carolina 27609.

1	21 NCAC 46 .1819 is adopted as published in 35:8 NCR 848 as follows:
2	
3	21 NCAC 46 .1819 COVID-19 DRUG PRESERVATION RULE
4	(a) The following drugs are "Restricted Drugs" as that term is used in this Rule:
5	(1) Hydroxychloroquine;
6	(2) Chloroquine:
7	(3) Lopinavir-ritonavir;
8	(4) Ribavirin;
9	(5) Darunavir.
10	(b) A pharmacist shall fill or refill a prescription for a Restricted Drug only if that prescription bears a written
11	diagnosis from the prescriber consistent with the evidence for its use.
12	(c) When a patient has been diagnosed with COVID-19, any prescription of a Restricted Drug for the treatment of
13	COVID-19 shall:
14	(1) Indicate on the prescription order that the patient has been diagnosed with COVID-19;
15	(2) Be limited to no more than a 14-day supply; and
16	(3) Not be refilled, unless a new prescription order is issued in conformance with this Rule, including
17	not being refilled through an emergency prescription refill.
18	(d) A pharmacist shall not fill or refill a prescription for a Restricted Drug for the prevention of, or in anticipation
19	of, the contraction of COVID-19 by someone who has not yet been diagnosed.
20	(e) A prescription for a Restricted Drug may be transmitted orally only if all information required by this Rule is
21	provided to the pharmacy by the prescriber or the prescriber's agent, and that information is recorded in writing by
22	the pharmacy, along with the identity of the prescriber or prescriber's agent transmitting the prescription.
23	(f) This Rule does not affect orders for administration to inpatients of health care facilities.
24	(g) This Rule does not apply to prescriptions for a Restricted Drug for a patient previously established on that
25	particular Restricted Drug on or before March 10, 2020.
26	
27	History Note: Authority G.S. 90-85.6; 90-85.26; 90-85.32;
28	Emergency Adoption Eff. April 1, 2020;
29	Temporary Adoption Eff. June 26, 2020;
30	Adoption Eff. February 1, 2021.